These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 32808890

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Renal function, nephrogenic systemic fibrosis and other adverse reactions associated with gadolinium-based contrast media.
    Canga A, Kislikova M, Martínez-Gálvez M, Arias M, Fraga-Rivas P, Poyatos C, de Francisco AL.
    Nefrologia; 2014; 34(4):428-38. PubMed ID: 25036056
    [Abstract] [Full Text] [Related]

  • 5. Current status of nephrogenic systemic fibrosis.
    Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H.
    Clin Radiol; 2014 Jul; 69(7):661-8. PubMed ID: 24582176
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment.
    Alfano G, Fontana F, Ferrari A, Solazzo A, Perrone R, Giaroni F, Torricelli P, Cappelli G.
    Magn Reson Imaging; 2020 Jul; 70():1-4. PubMed ID: 32112811
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The Risk of Nephrogenic Systemic Fibrosis in Group II and III Gadolinium-Based Contrast Agents.
    Costa AF.
    Can Assoc Radiol J; 2020 Nov; 71(4):536. PubMed ID: 32063014
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Safety of Gadolinium-Based Contrast Agents in Patients with Stage 4 and 5 Chronic Kidney Disease: a Radiologist's Perspective.
    Soloff EV, Wang CL.
    Kidney360; 2020 Feb 27; 1(2):123-126. PubMed ID: 35372905
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.